August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...

Pollen allergy symptoms can really wipe you out with a host of miserable issues. Here's how to recognize pollen, manage ...

Aquestive Therapeutics’ Anaphylm AQST-109 epinephrine sublingual film demonstrated durability despite testing in extreme ...

Erectile dysfunction (ED) is more common than most people think, yet it’s still a topic many shy away from discussing. The ...

From the Christ Hospital Health Network Blog Esther Cheng, MD, The Christ Hospital Physicians – Ear, Nose & Throat With spring in the air, if you have seasonal allergies, your sneezing ...

In moderate to severe pain from blunt trauma, sublingual sufentanil was not more effective than standard care in reducing pain at 30 minutes.

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (”Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, today provided an update on its two patent ...

Dives Deep with CEO Kraig Higginson to Discuss Aspire's Mission to Enhance Efficacy and Reduce Side EffectsNew York, New ...

M.D., an allergist and immunologist at George Washington University in Washington, D.C., said in a statement. "In addition to the convenience of sublingual administration, Odactra has been shown to ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

part of Glatt Group, a vertically integrated pharmaceutical services company with FDA- and EU-approved sites operating under cGMP conditions, has undertaken FDA-required testing of the Company’s ...

HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent ...